Literature DB >> 29471038

Co-delivery nanoparticle to overcome metastasis promoted by insufficient chemotherapy.

Qing Zhou1, Yihui Li1, Yanhong Zhu1, Chan Yu1, Haibo Jia2, Binghao Bao2, Hang Hu1, Chen Xiao1, Jianqi Zhang1, Xiaofan Zeng1, Ying Wan1, Huibi Xu1, Zifu Li3, Xiangliang Yang4.   

Abstract

Heterogeneous distribution of drug inside tumor is ubiquitous, causing regional insufficient chemotherapy, which might be the hotbed for drug resistance, tumor cell repopulation and metastasis. Herein, we verify, for the first time, that heterogeneous drug distribution induced insufficient chemotherapy would accelerate the process of epithelial mesenchymal transition (EMT), consequently resulting in the promotion of tumor metastasis. To eliminate the insufficient chemotherapy promoted metastasis, we conceived a co-delivery strategy by hydroxyethyl starch-polylactide (HES-PLA) nanoparticle, in which DOX and TGF-β receptor inhibitor, LY2157299 (LY), were administered together. In vitro and in vivo studies demonstrate that this co-delivery strategy can simultaneously suppress primary tumor and distant metastasis. Further study on immunofluorescence images of primary tumor verifies that low dose of DOX exasperates the EMT process, whereas the co-delivery nanoparticle can dramatically inhibit the progression of EMT. We reveal the impact of heterogeneous drug distribution on tumor metastasis and develop an effective co-delivery strategy to suppress the metastasis, providing guidance for clinical cancer therapy.
Copyright © 2018 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Co-delivery strategy; EMT; Heterogeneous drug distribution; Insufficient chemotherapy; Tumor metastasis

Mesh:

Substances:

Year:  2018        PMID: 29471038     DOI: 10.1016/j.jconrel.2018.02.026

Source DB:  PubMed          Journal:  J Control Release        ISSN: 0168-3659            Impact factor:   9.776


  12 in total

Review 1.  Hydroxyethyl starch and its derivatives as nanocarriers for delivery of diagnostic and therapeutic agents towards cancers.

Authors:  Ronghua Tan; Ying Wan; Xiangliang Yang
Journal:  Biomater Transl       Date:  2020-12-28

2.  Biodegradable electrospun nanofibrous platform integrating antiplatelet therapy-chemotherapy for preventing postoperative tumor recurrence and metastasis.

Authors:  Jianye Li; Jiaojiao Li; Yuzhu Yao; Tuying Yong; Nana Bie; Zhaohan Wei; Xin Li; Shiyu Li; Jiaqi Qin; Haibo Jia; Qing Du; Xiangliang Yang; Lu Gan
Journal:  Theranostics       Date:  2022-04-24       Impact factor: 11.600

Review 3.  What Zebrafish and Nanotechnology Can Offer for Cancer Treatments in the Age of Personalized Medicine.

Authors:  María Cascallar; Sandra Alijas; Alba Pensado-López; Abi Judit Vázquez-Ríos; Laura Sánchez; Roberto Piñeiro; María de la Fuente
Journal:  Cancers (Basel)       Date:  2022-04-30       Impact factor: 6.575

Review 4.  Engineering nanoparticles to reprogram radiotherapy and immunotherapy: recent advances and future challenges.

Authors:  Jing Jin; Qijie Zhao
Journal:  J Nanobiotechnology       Date:  2020-05-14       Impact factor: 10.435

Review 5.  A Perspective on Polylactic Acid-Based Polymers Use for Nanoparticles Synthesis and Applications.

Authors:  Tommaso Casalini; Filippo Rossi; Andrea Castrovinci; Giuseppe Perale
Journal:  Front Bioeng Biotechnol       Date:  2019-10-11

6.  Balancing the stability and drug activation in adaptive nanoparticles potentiates chemotherapy in multidrug-resistant cancer.

Authors:  Jianqin Wan; Lingling Huang; Jiangting Cheng; Huangfu Qi; Jiahui Jin; Hangxiang Wang
Journal:  Theranostics       Date:  2021-02-19       Impact factor: 11.556

Review 7.  Targeting transforming growth factor-β signaling for enhanced cancer chemotherapy.

Authors:  Jitang Chen; Ze-Yang Ding; Si Li; Sha Liu; Chen Xiao; Zifu Li; Bi-Xiang Zhang; Xiao-Ping Chen; Xiangliang Yang
Journal:  Theranostics       Date:  2021-01-01       Impact factor: 11.556

8.  Suppressing Sart1 to modulate macrophage polarization by siRNA-loaded liposomes: a promising therapeutic strategy for pulmonary fibrosis.

Authors:  Ting Pan; Qing Zhou; Kang Miao; Lei Zhang; Guorao Wu; Jun Yu; Yongjian Xu; Weining Xiong; Yong Li; Yi Wang
Journal:  Theranostics       Date:  2021-01-01       Impact factor: 11.556

Review 9.  Hydroxyethyl starch based smart nanomedicine.

Authors:  Huimin Wang; Hang Hu; Hai Yang; Zifu Li
Journal:  RSC Adv       Date:  2021-01-14       Impact factor: 3.361

10.  Protein Encapsulation of Experimental Anticancer Agents 5F 203 and Phortress: Towards Precision Drug Delivery.

Authors:  Alastair F Breen; David Scurr; Maria Letizia Cassioli; Geoffrey Wells; Neil R Thomas; Jihong Zhang; Lyudmila Turyanska; Tracey D Bradshaw
Journal:  Int J Nanomedicine       Date:  2019-12-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.